Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
AbbVie
(NY:
ABBV
)
197.55
+1.18 (+0.60%)
Official Closing Price
Updated: 7:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about AbbVie
< Previous
1
2
3
4
5
6
7
8
9
...
66
67
Next >
This Is What Whales Are Betting On AbbVie
May 22, 2024
Via
Benzinga
7 Safe-Haven Stocks to Weather Any Storm
May 22, 2024
Explore top safe-haven stocks to buy now for stability and consistent growth during economic turbulence and uncertainty.
Via
InvestorPlace
A Must-Own Stock for Any Portfolio
May 22, 2024
This company offers growth, high yield, and dividend growth.
Via
The Motley Fool
2 Billion More Reasons to Buy AbbVie Stock
May 22, 2024
This pharma giant just made a smart strategic acquisition.
Via
The Motley Fool
3 S&P 500 Stocks That Have Proven Themselves Recession-Proof
May 20, 2024
Corrections are a part of investing and investors would be smart to have these three S&P 500 stocks to buy when the inevitable happens.
Via
InvestorPlace
Topics
Stocks
Exposures
US Equities
1 Wall Street Analyst Thinks AbbVie Stock Is Going to $200. Is It a Buy at Around $165?
May 20, 2024
Revenue growth during what should be a disastrous patent cliff is encouraging.
Via
The Motley Fool
Topics
Intellectual Property
Exposures
Intellectual Property
The Analyst Verdict: AbbVie In The Eyes Of 5 Experts
May 17, 2024
Via
Benzinga
$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,000 Today
May 16, 2024
Via
Benzinga
Unpacking the Latest Options Trading Trends in AbbVie
May 14, 2024
Via
Benzinga
Cannabis Meets Prescription Drugs, Steroids And Ketamine In Schedule III: What It Means, Key Stocks To Watch
May 18, 2024
President Joe Biden's administration is moving to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act (CSA).
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
10 Stocks to Build a Dividend Portfolio With
May 18, 2024
All 10 of these stocks pay reliable and growing dividends.
Via
The Motley Fool
AbbVie Is 'Successfully Positioned To Absorb Humira Biosimilar Erosion': Analyst
May 17, 2024
Cantor Fitzgerald initiates coverage on AbbVie with an Overweight rating and a $200 price target. AbbVie is set to manage Humira biosimilar erosion, drive growth with Skyrizi, Rinvoq, and emraclidine,...
Via
Benzinga
7 Value Stocks to Buy and Hold for a Decade of Dominance
May 17, 2024
Discover the enduring value of seven key value stocks to buy and hold in diverse sectors, presenting unparalleled opportunities.
Via
InvestorPlace
(ABBV) - Analyzing AbbVie's Short Interest
May 10, 2024
Via
Benzinga
3 Reasons to Buy AbbVie Stock on the Dip
May 05, 2024
A little patience with the drugmaker should pay off.
Via
The Motley Fool
$1000 Invested In This Stock 10 Years Ago Would Be Worth $3,100 Today
May 02, 2024
Via
Benzinga
Wall Street Favorites: 3 Retirement Stocks With Strong Buy Ratings for May 2024
May 16, 2024
Amid the strong run in the market, investors thinking about long-term goals should consider these strongly endorsed retirement stocks to buy.
Via
InvestorPlace
Topics
Retirement
Exposures
Pension
Will Pharma And Healthcare Have Competitive Edge In Cannabis Post-Rescheduling? Data Analytics Expert Weighs In
May 14, 2024
Roy Bingham, CEO of BDSA, anticipates substantial growth in the U.S. cannabis market, projecting sales to reach nearly $46 billion by 2028.
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
3 Magnificent Stocks That Are Passive Income Machines
May 14, 2024
These three companies have track records that should please investors.
Via
The Motley Fool
What Is the Dividend Payout for AbbVie Stock?
May 13, 2024
The pharmaceutical company isn't just a quality healthcare holding. It's a compelling income investment as well.
Via
The Motley Fool
Healthcare And Biotech Investing 101: What You Need To Know.
May 13, 2024
Healthcare as a sector represents only about 12% of the S&P 500. If you want to overweight healthcare as a sector you need to add equities. Healthcare is usually a defensive sector because of...
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
Earn $1000 Every Month From These 3 Stocks
May 11, 2024
All 3 companies pay growing dividends.
Via
The Motley Fool
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever.
May 11, 2024
These pharmaceutical companies are top-notch dividend growth stocks for the future.
Via
The Motley Fool
3 Rock-Solid Dividend Stocks That Are Ideal for Retirees
May 10, 2024
These are low-risk stocks with high yields.
Via
The Motley Fool
Biotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare
May 07, 2024
Investors concerned about broader market undulations may want to consider the resilience narrative of these biotech stocks to buy.
Via
InvestorPlace
AbbVie Tracking for New Highs in 2024
May 07, 2024
Future Dividend King AbbVie is tracking for new highs as the shift away from Humira-based business gains momentum with new treatments and acquisitions.
Via
MarketBeat
Topics
Earnings
Exposures
Financial
3 Biotech Stocks to Double Your Money in the Next 24 Months
May 06, 2024
The biotech sector offers significant potential for growth. These 3 biotech stocks to double your money are noteworthy candidates.
Via
InvestorPlace
MarketBeat Week in Review – 4/29 - 5/3
May 04, 2024
Apple, Amgen, and a weak jobs report helped move the market higher as investors temporarily looked past the possibility of no interest rate cuts in 2024
Via
MarketBeat
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
7 Safe Haven Stocks That Can Withstand the Market’s Worst Meltdowns
April 30, 2024
Safe haven stocks offer stability even during market fall in communication, financials, healthcare, energy and consumer staples.
Via
InvestorPlace
Analyst Sentiment, Revenue Growth Will Lead AbbVie Stock Higher
April 30, 2024
After falling nearly 6% based on concerns about Humira sales, AbbVie stock is recovering, and bullish analyst sentiment is likely to push the stock higher
Via
MarketBeat
< Previous
1
2
3
4
5
6
7
8
9
...
66
67
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.